Dengue Virus High-Throughput Fluorescent Assay

Available For: Non-exclusive licenses.

Summary

We have developed a novel fluorescent assay for the screening of small molecules targeting dengue virus.

The Technology and its Advantages

Our technology is based on stable cell lines expressing a replicon of dengue virus, optimised for assessing drug efficacy in vitro through incorporation of a fluorescent reporter element.

Market opportunity

Dengue hemorrhagic fever is a flavivirus with the major disease burden occurring in South East Asia, the Americas and the Western Pacific, but recent cases have been reported in Florida. It is possible that environmental warming may see increased distribution of dengue cases.

Further Information

Please contact Dr Barny Cox, Senior Business Manager |T: +44(0)20 7679 9160 |E: b.cox@uclb.com

The technology referred to herein is experimental in nature and UCL Business PLC makes no representations and gives no warranties of any kind, either express or implied, in relation to the technology and, in particular but without limiting the foregoing, UCL Business PLC gives no express or implied warranties of merchantability, satisfactory quality or fitness for a particular purpose.